Current policies being employed to limit spending can have serious consequences for patients, but a different benefit design approach could present an alternative strategy.
Current policies being employed to limit spending can have serious consequences for patients. In the April issue of The American Journal of Managed Care® (AJMC®), A. Mark Fendrick, MD, co-authored a paper that examined the relationship between consumer cost sharing for branded antidepressants and the initiation of branded therapy among patients who were filling a prescription for a generic medication to treat major depressive disorder.
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Read the paper:
Listen above or through one of these podcast services:Cost Sharing and Branded Antidepressant Initiation Among Patients Treated With Generics
Report Reveals Mounting Burdens of Drug Shortages on US Health System
June 27th 2025Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard and labor costs soaring—but the true impact may go far beyond limited medication access, threatening to disrupt the very foundations of how health systems operate.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen